Wednesday, 22 December 2010

Dihydrocodeine, Aspirin and Caffeine





Dosage Form: capsule
Dihydrocodeine bitartrate and aspirin and caffeine

Dihydrocodeine, Aspirin and Caffeine Description


Each capsule contains 16 mg drocode (dihydrocodeine) bitartrate (Warning–may be habit-forming), 356.4 mg aspirin, and 30 mg caffeine.


The inactive ingredients present are alginic acid, cellulose, D&C Red 28, FD&C Blue 1, gelatin, iron oxides, stearic acid, and titanium dioxide.



Dihydrocodeine, Aspirin and Caffeine - Clinical Pharmacology


Dihydrocodeine is a semisynthetic narcotic analgesic, related to codeine, with multiple actions qualitatively similar to those of codeine; the most prominent of these involve the central nervous system and organs with smooth-muscle components. The principal action of therapeutic value is analgesia.


The capsule also contains the nonnarcotic antipyretic-analgesic, aspirin.



Indications and Usage for Dihydrocodeine, Aspirin and Caffeine


For the relief of moderate to moderately severe pain.



Contraindications


Hypersensitivity to dihydrocodeine, codeine, or aspirin.



Warnings


Salicylates should be used with extreme caution in the presence of peptic ulcer or coagulation abnormalities.



Drug Dependence


Dihydrocodeine can produce drug dependence of the codeine type and therefore has the potential of being abused. Psychic dependence, physical dependence, and tolerance may develop upon repeated administration of dihydrocodeine, and it should be prescribed and administered with the same degree of caution appropriate to the use of other oral narcotic-containing medications. Like other narcotic-containing medications, dihydrocodeine is subject to the provisions of the Federal Controlled Substances Act.



Usage in Ambulatory Patients


Dihydrocodeine may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a car or operating machinery. The patient using the dihydrocodeine bitartrate, aspirin, and caffeine capsule should be cautioned accordingly.



Interactions with other Central Nervous System Depressants


Patients receiving other narcotic analgesics, general anesthetics, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) concomitantly with the dihydrocodeine bitartrate, aspirin, and caffeine capsule may exhibit an additive CNS depression. When such combined therapy is contemplated, the dose of one or both agents should be reduced.



Usage in Pregnancy


Reproduction studies have not been performed in animals. There is no adequate information on whether this drug may affect fertility in human males and females or has a teratogenic potential or other adverse effect on the fetus.



Usage in Children


Preparations containing aspirin should be kept out of the reach of children. The dihydrocodeine bitartrate, aspirin, and caffeine capsule is not recommended for patients 12 years of age and under. Since there is no experience in chil­dren who have received this drug, safety and efficacy in children have not been established.



Precautions


The dihydrocodeine bitartrate, aspirin, and caffeine capsule should be given with caution to certain patients, such as the elderly or debilitated.



Drug Interactions


The CNS-depressant effects of the dihydrocodeine bitartrate, aspirin, and caffeine capsule may be additive with that of other CNS depressants. See “WARNINGS.”


Aspirin may enhance the effects of anticoagulants and inhibit the uricosuric effects of uricosuric agents.



Geriatric Use


Clinical studies of the dihydrocodeine bitartrate, aspirin, and caffeine capsule did not include sufficient numbers of subjects aged 65 and over to determine whether elderly subjects respond differently from younger subjects.


In general, dose selection for an elderly patient should be cautious, starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.



Adverse Reactions


The most frequently observed reactions include lightheadedness, dizziness, drowsiness, sedation, nausea, vomiting, constipation, pruritus, and skin reactions.



Dihydrocodeine, Aspirin and Caffeine Dosage and Administration


Dosage should be adjusted according to the severity of the pain and the response of the patient. The dihydrocodeine bitartrate, aspirin, and caffeine capsule is given orally. The usual adult dose is two capsules every 4 hours as need­ed for pain.



How is Dihydrocodeine, Aspirin and Caffeine Supplied


Dihydrocodeine bitartrate, aspirin, and caffeine Capsules are blue and gray, marked “CP” and “419”, supplied in:




Bottles of 100 capsules; NDC 57902-419-88

 

Store at room temperature, approx. 25°C (77°F). Keep tightly closed.

 

Dispense in tight container.

Manufactured for and distributed by:


EUSA Pharma (USA), Inc.

One Summit Square, Suite 201

1717 Langhorne Newtown Rd.

Langhorne, PA 19047
www.eusapharma.com

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL


NDC 57902-419-88


100 Capsules


Dihydrocodeine bitartrate, aspirin, and caffeine capsules


Each capsule contains: 16 mg drocode (dihydrocodeine) bitartrate (Warning–may

be habit-forming), 356.4 mg aspirin, and 30 mg caffeine.


SEALED FOR YOUR PROTECTION


Rx Only


EUSA Pharma (USA), Inc.










DIHYDROCODEINE BITARTRATE AND ASPIRIN AND CAFFEINE  DC
dihydrocodeine bitartrate and aspirin and caffeine  capsule










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)57902-419 (49708-419)
Route of AdministrationORALDEA ScheduleCIII    














Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
DIHYDROCODEINE BITARTRATE (DIHYDROCODEINE)DIHYDROCODEINE BITARTRATE16 mg
ASPIRIN (ASPIRIN)ASPIRIN356.4 mg
CAFFEINE (CAFFEINE)CAFFEINE30 mg




















Inactive Ingredients
Ingredient NameStrength
ALGINIC ACID 
POWDERED CELLULOSE 
D&C RED NO. 28 
FD&C BLUE NO. 1 
GELATIN 
FERROSOFERRIC OXIDE 
STEARIC ACID 
TITANIUM DIOXIDE 


















Product Characteristics
ColorBLUE, GRAYScoreno score
ShapeCAPSULESize19mm
FlavorImprint CodeCP;419
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
157902-419-88100 CAPSULE In 1 BOTTLENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA01148304/25/2011


Labeler - EUSA Pharma (USA), Inc. (038596862)
Revised: 04/2011EUSA Pharma (USA), Inc.

More Dihydrocodeine, Aspirin and Caffeine resources


  • Dihydrocodeine, Aspirin and Caffeine Side Effects (in more detail)
  • Dihydrocodeine, Aspirin and Caffeine Use in Pregnancy & Breastfeeding
  • Dihydrocodeine, Aspirin and Caffeine Drug Interactions
  • Dihydrocodeine, Aspirin and Caffeine Support Group
  • 0 Reviews for Dihydrocodeine, Aspirin and Caffeine - Add your own review/rating


Compare Dihydrocodeine, Aspirin and Caffeine with other medications


  • Pain

No comments:

Post a Comment